Dr. Hanns-Georg Klein
Dr. Hanns-Georg Klein

Dr. Hanns-Georg Klein

Facharzt für Laboratoriumsmedizin, Medizinische Genetik, MVZ

Day2, July 6, 4:30 p.m., #7 Livetalk:
Präzisionsmedizin: Die Chancen der frühen Diagnose

After finishing Medical School in Erlangen and Munich, Germany, Dr. Klein´s professional stations included postdoctoral fellowships at the Department of Physiology at the University of Munich and at the National Heart, Lung and Blood Institute (NHLBI) in Bethesda. His received his clinical training at the Medical Policlinic of the University of Munich and at the Department of Clinical Chemistry at the University Hospital Grosshadern.

After successfully passing the board examinations for Clinical Pathology and Human Genetics, Dr. Klein left the university and started his career as an entrepreneur. He founded MEDIGENOMIX GmbH, a genomic services company, which today is part of the Eurofins group. Shortly after, Dr. Klein founded the Center for Human Genetics and Laboratory Diagnostics in Martinsried and IMGM Laboratories GmbH, being the Medical Director and CEO of both companies to date. In a joint transaction in 2018, both companies have become part of the international Medicover group (Sweden). In 2019, Dr. Klein founded acmaios GmbH, an investment company for seed financing start-ups in biotech and digital health.

Dr. Klein is author of more than 120 scientific publications and book contributions and serves as a field editor for the Journal of Laboratory Medicine. He is also a member of several medical associations and teaches Clinical Chemistry at the University of Munich. Dr. Klein served as a board member of the M4 cluster “Personalized Medicine” steering committee in Martinsried, an initiative supported by the State Government of Bavaria to improve treatment of cancer and other diseases. From 2017 until 2022 he served as elected Board Member of the Association of German Human Geneticists (BVDH). Recently, Dr. Klein was a founding member and appointed Vice-President of the newly formed network initiative “Personalized Medicine".